Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

FibroGen Inc

FGEN
Current price
0.62 USD +0.0094 USD (+1.54%)
Last closed 0.58 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 61 796 984 USD
Yield for 12 month -95.75 %
Week
Month
Year
FGEN
21.11.2021 - 28.11.2021

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158

Analytics

WallStreet Target Price

1.03 USD

P/E ratio

Dividend Yield

Current Year

+140 734 000 USD

Last Year

+235 309 000 USD

Current Quarter

+40 134 000 USD

Last Quarter

+44 319 000 USD

Current Year

+120 454 000 USD

Last Year

+222 438 000 USD

Current Quarter

+35 891 000 USD

Last Quarter

+38 611 000 USD

Key Figures FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -245 784 992 USD
Operating Margin TTM -126.77 %
PE Ratio
Return On Assets TTM -29.99 %
PEG Ratio
Return On Equity TTM -1015.79 %
Wall Street Target Price 1.03 USD
Revenue TTM 154 980 992 USD
Book Value -1.6 USD
Revenue Per Share TTM 1.61 USD
Dividend Share
Quarterly Revenue Growth YOY 155.1 %
Dividend Yield
Gross Profit TTM -159 212 000 USD
Earnings Share -3.06 USD
Diluted Eps TTM -3.06 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 53.6 %
Profit Margin -189.81 %

Dividend Analytics FGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 61.3497
Enterprise Value Revenue 0.1892
Price Sales TTM 0.3987
Enterprise Value EBITDA -0.0806
Price Book MRQ 53.8258

Financials FGEN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators FGEN

For 52 weeks

0.33 USD 25.69 USD
50 Day MA 0.61 USD
Shares Short Prior Month 13 514 235
200 Day MA 8.96 USD
Short Ratio 7.05
Shares Short 15 286 471
Short Percent 20.48 %